Table 3.

Comparison of vital parameters and laboratory values before starting therapy with angiotensin receptor neprilysin inhibitors and at 6-month follow-up.

Clinical and laboratory parameters	Baseline value of patients who are symptomatic despite ARNI (n = 104)	Values at 6-months follow-up after initiation of SGLT2i (n = 104)	Mean/Median ± SE change in parameters from baseline after initiation of SGLTi2 at 6-months follow-up	p-Value
Primary Outcome
Ejection fraction [%]	29 ± 4	38 ± 5	+9.00 ± 0.628	<0.001
Secondary Outcomes
NYHA Class (Median)	3.83 ± 0.17	1.53 ± 0.24	−2.3 ± 0.2	<0.001
Systolic BP [mmHg]	124 ± 21	107 ± 12	−17.0 ± 2.372	<0.001
Diastolic BP [mmHg]	81 ± 9	78 ± 5	−3.0 ± 1.010	0.0033
Heart rate [bpm]	106 ± 7	74 ± 17.9	−32.0 ± 3.234	<0.001
NT-proBNP [pg/mL]	13,607 ± 1874	1100 ± 682	−12507 ± 246.92	<0.001
Creatinine [mg/dL]@	0.88 ± 0.19	0.9 ± 0.31	+0.02 ± 0.036	0.575
Potassium [mEq/L]	4.55 ± 0.4	4.6 ± 0.5	+0.05 ± 0.06	0.426

@A decline in renal function was defined as end-stage renal disease or a decrease of 50% or more in the estimated glomerular filtration rate (eGFR) from the initial value or a decrease in the eGFR of more than 30 mL per minute per 1.73 m², to less than 60 mL per minute per 1.73 m². N-terminal pro hormone brain natriuretic peptide = NT-proBNP; Nonsignificant = NS; Beats per minute = BPM; Blood Pressure = BP; NYHA = New York Heart Association.